Literature DB >> 11369513

Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3.

R Srinivasan1, K E Leverton, H Sheldon, H C Hurst, C Sarraf, W J Gullick.   

Abstract

The ERBB3 gene is expressed as a 6.2- and a 1.4-kb transcript. The former encodes the full-length transmembrane protein and the latter a truncated extracellular fragment consisting of 140 amino acids of the c-erbB-3 protein followed by 43 unique residues. We have examined the expression of the two ERBB3 transcripts by Northern blotting in cancer cell lines and normal human fetal and adult tissues. We expressed the truncated receptor fragment and showed that it was glycosylated, probably with a single N-linked complex sugar chain, and that the protein was a 58-kDa disulphide-linked dimer. We were able to crosslink iodinated neuregulin (NRG)-1beta to the full-length solubilised receptor but not to the truncated dimeric protein. Using Western blot analysis, the truncated protein was shown to be present in cell lysates and, using immunoelectron microscopy, in vesicular structures within cells and associated with the plasma cell membrane.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369513     DOI: 10.1016/s0898-6568(01)00155-3

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  7 in total

1.  High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC).

Authors:  B Sonnweber; M Dlaska; S Skvortsov; S Dirnhofer; T Schmid; W Hilbe
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

2.  Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Authors:  Liqun Chen; Salma Siddiqui; Swagata Bose; Benjamin Mooso; Alfredo Asuncion; Roble G Bedolla; Ruth Vinall; Clifford G Tepper; Regina Gandour-Edwards; Xubao Shi; Xiao-Hua Lu; Javed Siddiqui; Arul M Chinnaiyan; Rohit Mehra; Ralph W Devere White; Kermit L Carraway; Paramita M Ghosh
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

Review 3.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

4.  Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.

Authors:  Xiu Li Zhang; Yun Sheng Yang; Dong Ping Xu; Jian Hui Qu; Ming Zhou Guo; Yan Gong; Jin Huang
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

Review 5.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

6.  ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).

Authors:  Dane A Hayes; Dale A Kunde; Robyn L Taylor; Stephen B Pyecroft; Sukhwinder Singh Sohal; Elizabeth T Snow
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

7.  HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.

Authors:  Gregory Weitsman; Paul R Barber; Lan K Nguyen; Katherine Lawler; Gargi Patel; Natalie Woodman; Muireann T Kelleher; Sarah E Pinder; Mark Rowley; Paul A Ellis; Anand D Purushotham; Anthonius C Coolen; Boris N Kholodenko; Borivoj Vojnovic; Cheryl Gillett; Tony Ng
Journal:  Oncotarget       Date:  2016-08-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.